NCT00279279

Brief Summary

The purpose of this study is to test specific device programming in patients without a previous history of a life-threatening, abnormally fast heartbeat who are implanted with a Medtronic ICD (Implantable Cardioconverter Defibrillator) or ICD with CRT (Cardiac Resynchronozation Therapy) device. The information learned from this study could be used to guide physicians in future ICD or CRT device programming.

Trial Health

90
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
700

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Oct 2003

Typical duration for not_applicable

Geographic Reach
2 countries

32 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2003

Completed
2.3 years until next milestone

First Submitted

Initial submission to the registry

January 17, 2006

Completed
2 days until next milestone

First Posted

Study publicly available on registry

January 19, 2006

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2006

Completed
Last Updated

October 26, 2006

Status Verified

October 1, 2006

First QC Date

January 17, 2006

Last Update Submit

October 25, 2006

Conditions

Keywords

Implantable cardioverter defibrillator (ICD)Sudden Cardiac DeathPrimary Prevention

Outcome Measures

Primary Outcomes (1)

  • Demonstrate that patients programmed using a prescribed set of parameters have a lower rate of cardiac syncope, symptoms of fast heart rate, VT/VF events and cardioversion or defibrillation shocks compared to patients programmed per physician discretion

Secondary Outcomes (7)

  • Evaluate the percentage of inappropriate VT/VF detections

  • characterize the true incidence of VT/VF detections

  • therapy efficacy

  • time to first inappropriate VT/VF detection

  • incidence of untreated but monitored VT

  • +2 more secondary outcomes

Interventions

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patient is a candidate for a non-replacement Medtronic ICD device from the Marquis family or has had a non-replacement Medtronic Marquis based ICD system implanted within the previous 6 months and has not had any appropriately treated spontaneous VT/VF episodes during that time.

You may not qualify if:

  • Patient has history of spontaneous sustained symptomatic ventricular arrhythmias.
  • If patient has had an electrophysiology test in the past, and has sustained inducible VT \<180 bpm.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (32)

Unknown Facility

Birmingham, Alabama, United States

Location

Unknown Facility

Mesa, Arizona, United States

Location

Unknown Facility

Phoenix, Arizona, United States

Location

Unknown Facility

San Diego, California, United States

Location

Unknown Facility

San Pablo, California, United States

Location

Unknown Facility

Newark, Delaware, United States

Location

Unknown Facility

Fort Lauderdale, Florida, United States

Location

Unknown Facility

Jacksonville, Florida, United States

Location

Unknown Facility

Merrit Island, Florida, United States

Location

Unknown Facility

Columbus, Georgia, United States

Location

Unknown Facility

Maywood, Illinois, United States

Location

Unknown Facility

Rockford, Illinois, United States

Location

Unknown Facility

Topeka, Kansas, United States

Location

Unknown Facility

Portland, Maine, United States

Location

Unknown Facility

Silver Spring, Maryland, United States

Location

Unknown Facility

Takoma Park, Maryland, United States

Location

Unknown Facility

Boston, Massachusetts, United States

Location

Unknown Facility

Royal Oak, Michigan, United States

Location

Unknown Facility

Minneapolis, Minnesota, United States

Location

Unknown Facility

Paterson, New Jersey, United States

Location

Unknown Facility

Buffalo, New York, United States

Location

Unknown Facility

New York, New York, United States

Location

Unknown Facility

Columbus, Ohio, United States

Location

Unknown Facility

Elyria, Ohio, United States

Location

Unknown Facility

Bethlehem, Pennsylvania, United States

Location

Unknown Facility

Lancaster, Pennsylvania, United States

Location

Unknown Facility

Columbia, South Carolina, United States

Location

Unknown Facility

Nashville, Tennessee, United States

Location

Unknown Facility

Amarillo, Texas, United States

Location

Unknown Facility

Kirkland, Washington, United States

Location

Unknown Facility

Morgantown, West Virginia, United States

Location

Unknown Facility

San Juan, Puerto Rico

Location

Related Publications (2)

  • van Gelder IC, Phan HM, Wilkoff BL, Brown ML, Rogers T, Peterson BJ, Birgersdotter-Green UM. Prognostic significance of atrial arrhythmias in a primary prevention ICD population. Pacing Clin Electrophysiol. 2011 Sep;34(9):1070-9. doi: 10.1111/j.1540-8159.2011.03124.x. Epub 2011 May 23.

  • Wilkoff BL, Williamson BD, Stern RS, Moore SL, Lu F, Lee SW, Birgersdotter-Green UM, Wathen MS, Van Gelder IC, Heubner BM, Brown ML, Holloman KK; PREPARE Study Investigators. Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study. J Am Coll Cardiol. 2008 Aug 12;52(7):541-50. doi: 10.1016/j.jacc.2008.05.011.

MeSH Terms

Conditions

Tachycardia, VentricularVentricular FibrillationSyncopeDeath, Sudden, Cardiac

Condition Hierarchy (Ancestors)

TachycardiaArrhythmias, CardiacHeart DiseasesCardiovascular DiseasesCardiac Conduction System DiseasePathologic ProcessesPathological Conditions, Signs and SymptomsUnconsciousnessConsciousness DisordersNeurobehavioral ManifestationsNeurologic ManifestationsNervous System DiseasesSigns and SymptomsHeart ArrestDeath, SuddenDeath

Study Officials

  • Bruce Wilkoff, M.D

    The Cleveland Clinic

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

January 17, 2006

First Posted

January 19, 2006

Study Start

October 1, 2003

Study Completion

May 1, 2006

Last Updated

October 26, 2006

Record last verified: 2006-10

Locations